An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment
Status: | Recruiting |
---|---|
Conditions: | Healthy Studies, Gastrointestinal |
Therapuetic Areas: | Gastroenterology, Other |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 10/19/2013 |
Start Date: | February 2013 |
Contact: | Brenda Souza |
Phone: | (609) 512-4129 |
An Open-label, Single-dose,Intravenous Administration Study to Compare the Pharmacokinetics and Safety of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment With Matching Healthy Subjects
To evaluate and compare the pharmacokinetics and safety of ONO-2745/CNS 7056 in subjects
with the hepatic impairment and matched healthy subjects.
In Part One, 8 subjects with moderate hepatic impairment (Child Pugh Scale B) and 8 matched
healthy subjects will be enrolled. In Part 2, 8 subjects with mild hepatic impairment
(Child-Pugh Scale A) and 8 matched healthy subjects will be enrolled. In Part 3, 3 subjects
with severe hepatic impairment (Child-Pugh Scale C) will be enrolled. Parts 2 and 3 will
only be initiated if the criteria per protocol is met in Part One. The pharmacokinetics and
safety profiles will be compared between hepatic impaired subjects and healthy subjects.
Inclusion Criteria:
- Males or females between 18 and 65 years of age
- Negative test for the selected drugs of abuse at screening
Hepatic impaired subjects:
- Stable hepatic function and medication regimen for at least 28 days prior to
check-in
- Degree of hepatic impairment will be determined by the Child-Pugh Scale
Exclusion Criteria:
- Clinical manifestation of any disease (except hepatic impaired subjects)
- History of significant hypersensitivity, intolerance, or allergy to any drug
compound, including food, or other substance
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials